3,845 Shares in OptimizeRx Corp. (NASDAQ:OPRX) Bought by GAMMA Investing LLC

GAMMA Investing LLC bought a new position in OptimizeRx Corp. (NASDAQ:OPRX) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 3,845 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors also recently added to or reduced their stakes in OPRX. Whetstone Capital Advisors LLC purchased a new position in shares of OptimizeRx in the fourth quarter valued at about $6,563,000. Royce & Associates LP purchased a new position in shares of OptimizeRx in the fourth quarter valued at about $5,198,000. Kennedy Capital Management LLC increased its position in shares of OptimizeRx by 57.8% in the fourth quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company’s stock valued at $2,887,000 after acquiring an additional 217,676 shares during the period. Dimensional Fund Advisors LP increased its position in shares of OptimizeRx by 9.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company’s stock valued at $2,159,000 after acquiring an additional 39,740 shares during the period. Finally, Geode Capital Management LLC increased its position in shares of OptimizeRx by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 400,621 shares of the company’s stock valued at $1,948,000 after acquiring an additional 4,821 shares during the period. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx Trading Down 4.2%

NASDAQ:OPRX opened at $12.65 on Friday. OptimizeRx Corp. has a one year low of $3.78 and a one year high of $15.71. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.82 and a quick ratio of 2.82. The company’s 50-day simple moving average is $11.58 and its 200 day simple moving average is $8.06. The firm has a market capitalization of $234.03 million, a P/E ratio of -15.06, a PEG ratio of 4.40 and a beta of 1.34.

OptimizeRx (NASDAQ:OPRX) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of ($0.11) by $0.19. OptimizeRx had a negative net margin of 16.33% and a negative return on equity of 0.29%. The business had revenue of $21.93 million for the quarter, compared to analyst estimates of $18.69 million. As a group, analysts forecast that OptimizeRx Corp. will post -0.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on OPRX shares. Wall Street Zen upgraded shares of OptimizeRx from a “hold” rating to a “buy” rating in a research report on Thursday, May 22nd. Roth Capital restated a “buy” rating on shares of OptimizeRx in a research report on Tuesday, May 13th. Stifel Nicolaus lifted their target price on shares of OptimizeRx from $12.50 to $16.00 and gave the company a “buy” rating in a research note on Monday, June 9th. JMP Securities lifted their target price on shares of OptimizeRx from $11.00 to $14.00 and gave the company a “market outperform” rating in a research note on Tuesday, May 13th. Finally, Citigroup reaffirmed an “outperform” rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $10.81.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.